[{"id":"c121533e-47d9-4ac4-9593-e7db6d83a51b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06970132","created_at":"2025-09-07T01:34:43.364Z","updated_at":"2025-09-07T01:34:43.364Z","phase":"Phase 1/2","brief_title":"Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation","source_id_and_acronym":"NCT06970132","lead_sponsor":"Shouyao Holdings (Beijing) Co. LTD","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e conteltinib (SY-707) • SY-5933"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2025-05-14"},{"id":"12474215-8ccb-4758-b817-b0ea028361d5","acronym":"x-МАР","url":"https://clinicaltrials.gov/study/NCT06949982","created_at":"2025-07-19T13:21:59.299Z","updated_at":"2025-07-19T13:21:59.299Z","phase":"Phase 2","brief_title":"Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes","source_id_and_acronym":"NCT06949982 - x-МАР","lead_sponsor":"Sergey Orlov, MD","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • capecitabine • Stivarga (regorafenib) • methotrexate • hydroxychloroquine"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 03/17/2025","start_date":" 03/17/2025","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2025-05-04"},{"id":"e42e13ac-a207-4481-8490-407dcba3be1f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06939452","created_at":"2025-09-07T01:21:18.589Z","updated_at":"2025-09-07T01:21:18.589Z","phase":"Phase 2","brief_title":"A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression","source_id_and_acronym":"NCT06939452","lead_sponsor":"Yongxu Jia","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • oxaliplatin • Andewei (benmelstobart) • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 06/07/2023","start_date":" 06/07/2023","primary_txt":" Primary completion: 06/07/2025","primary_completion_date":" 06/07/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-04-22"},{"id":"cd9c94c5-ad9b-4ee8-a453-d749f2f2d4c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05111574","created_at":"2021-11-08T14:53:11.866Z","updated_at":"2025-02-25T12:38:02.656Z","phase":"Phase 2","brief_title":"Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery","source_id_and_acronym":"NCT05111574","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 99","initiation":"Initiation: 08/11/2022","start_date":" 08/11/2022","primary_txt":" Primary completion: 12/19/2025","primary_completion_date":" 12/19/2025","study_txt":" Completion: 12/19/2025","study_completion_date":" 12/19/2025","last_update_posted":"2025-02-24"},{"id":"f49513f4-2324-4f1a-bfa6-fcc569055fc2","acronym":"STAR-T","url":"https://clinicaltrials.gov/study/NCT05839951","created_at":"2023-05-03T15:04:35.012Z","updated_at":"2025-02-25T12:29:31.860Z","phase":"","brief_title":"An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions","source_id_and_acronym":"NCT05839951 - STAR-T","lead_sponsor":"Bayer","biomarkers":" KRAS • MSI","pipe":"","alterations":" ","tags":["KRAS • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 818","initiation":"Initiation: 04/24/2023","start_date":" 04/24/2023","primary_txt":" Primary completion: 03/14/2025","primary_completion_date":" 03/14/2025","study_txt":" Completion: 03/14/2025","study_completion_date":" 03/14/2025","last_update_posted":"2025-02-24"},{"id":"a8dbbb89-8bb1-4f12-ad96-eb67e83dce09","acronym":"","url":"https://clinicaltrials.gov/study/NCT00265798","created_at":"2021-01-18T00:54:12.869Z","updated_at":"2025-02-25T13:47:55.628Z","phase":"Phase 2","brief_title":"Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate","source_id_and_acronym":"NCT00265798","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KIT","pipe":" | ","alterations":" KIT expression","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • imatinib • sunitinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 09/14/2005","start_date":" 09/14/2005","primary_txt":" Primary completion: 02/11/2010","primary_completion_date":" 02/11/2010","study_txt":" Completion: 03/08/2025","study_completion_date":" 03/08/2025","last_update_posted":"2025-02-20"},{"id":"6280dfa5-ede9-4d89-a587-10249cd79abf","acronym":"AGORA-1","url":"https://clinicaltrials.gov/study/NCT05199051","created_at":"2022-01-20T15:53:56.079Z","updated_at":"2025-02-25T14:02:40.845Z","phase":"Phase 2","brief_title":"A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults with FLT3-ITD Relapse/refractory (R/R) AML","source_id_and_acronym":"NCT05199051 - AGORA-1","lead_sponsor":"Centre Antoine Lacassagne","biomarkers":" FLT3 • CD33","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3-TKD mutation • CD33 positive","tags":["FLT3 • CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3-TKD mutation • CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Xospata (gilteritinib) • Mylotarg (gemtuzumab ozogamicin)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/03/2023","start_date":" 06/03/2023","primary_txt":" Primary completion: 03/15/2027","primary_completion_date":" 03/15/2027","study_txt":" Completion: 03/15/2027","study_completion_date":" 03/15/2027","last_update_posted":"2025-02-19"},{"id":"19de6cba-154e-407a-90ae-62caa0401945","acronym":"PARERE","url":"https://clinicaltrials.gov/study/NCT04787341","created_at":"2021-03-08T12:53:54.161Z","updated_at":"2025-02-25T14:40:46.384Z","phase":"Phase 2","brief_title":"PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence","source_id_and_acronym":"NCT04787341 - PARERE","lead_sponsor":"Gruppo Oncologico del Nord-Ovest","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Vectibix (panitumumab) • Stivarga (regorafenib) • oxaliplatin • irinotecan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 214","initiation":"Initiation: 12/15/2020","start_date":" 12/15/2020","primary_txt":" Primary completion: 06/15/2025","primary_completion_date":" 06/15/2025","study_txt":" Completion: 12/15/2025","study_completion_date":" 12/15/2025","last_update_posted":"2025-02-14"},{"id":"9480eee5-c88d-4aa5-a04a-bfe171590b90","acronym":"INCB 84344-102","url":"https://clinicaltrials.gov/study/NCT03934372","created_at":"2021-01-18T19:22:38.750Z","updated_at":"2025-02-25T14:40:12.243Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors","source_id_and_acronym":"NCT03934372 - INCB 84344-102","lead_sponsor":"Incyte Biosciences International Sàrl","biomarkers":" FLT3 • ABL1 • BCR • RET • FGFR • BLM","pipe":" | ","alterations":" EGFR mutation • KIT mutation • FGFR mutation • RET mutation","tags":["FLT3 • ABL1 • BCR • RET • FGFR • BLM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • KIT mutation • FGFR mutation • RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Iclusig (ponatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/29/2020","start_date":" 01/29/2020","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-14"},{"id":"a1cc20b7-e120-4c96-ad2e-1583010cd20c","acronym":"CARE study","url":"https://clinicaltrials.gov/study/NCT04094610","created_at":"2021-01-18T20:02:04.781Z","updated_at":"2025-02-25T14:40:19.057Z","phase":"Phase 1/2","brief_title":"A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations","source_id_and_acronym":"NCT04094610 - CARE study","lead_sponsor":"Turning Point Therapeutics, Inc.","biomarkers":" ALK • ROS1 • NTRK1 • NTRK3 • NTRK2 • NTRK","pipe":" | ","alterations":" ALK fusion • ROS1 fusion • NTRK positive • NTRK fusion","tags":["ALK • ROS1 • NTRK1 • NTRK3 • NTRK2 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK fusion • ROS1 fusion • NTRK positive • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Augtyro (repotrectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 03/12/2020","start_date":" 03/12/2020","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-14"},{"id":"460f1e61-72a2-48bb-a37c-e804016f6240","acronym":"NCI-2021-06095","url":"https://clinicaltrials.gov/study/NCT05010122","created_at":"2021-08-18T15:53:42.501Z","updated_at":"2025-02-25T15:12:15.219Z","phase":"Phase 1/2","brief_title":"ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT05010122 - NCI-2021-06095","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Xospata (gilteritinib) • Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 07/08/2021","start_date":" 07/08/2021","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-13"},{"id":"99225106-dfaa-4574-8f8a-c62a8252d206","acronym":"","url":"https://clinicaltrials.gov/study/NCT04293562","created_at":"2021-01-18T20:50:03.431Z","updated_at":"2025-02-25T15:11:29.634Z","phase":"Phase 3","brief_title":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","source_id_and_acronym":"NCT04293562","lead_sponsor":"Children's Oncology Group","biomarkers":" FLT3","pipe":"","alterations":" ","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xospata (gilteritinib) • etoposide IV • methotrexate • Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation) • mitoxantrone • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Erwinase (erwinia asparaginase) • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate) • dexrazoxane"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1186","initiation":"Initiation: 07/21/2020","start_date":" 07/21/2020","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-13"},{"id":"fa25f52e-d775-44da-9710-a28c3fa442b5","acronym":"MIRAGE","url":"https://clinicaltrials.gov/study/NCT06275919","created_at":"2024-02-23T18:27:39.333Z","updated_at":"2025-02-25T15:14:15.952Z","phase":"Phase 2","brief_title":"Regorafenib for Recurrent Grade 2 and 3 Meningioma (MIRAGE Trial)","source_id_and_acronym":"NCT06275919 - MIRAGE","lead_sponsor":"Istituto Oncologico Veneto IRCCS","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stivarga (regorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 104","initiation":"Initiation: 09/23/2024","start_date":" 09/23/2024","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2025-02-13"},{"id":"917b48fd-6760-442b-9dca-351ad6f6d491","acronym":"","url":"https://clinicaltrials.gov/study/NCT02299141","created_at":"2021-01-17T17:53:09.705Z","updated_at":"2025-02-25T15:33:17.802Z","phase":"Phase 2","brief_title":"Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02299141","lead_sponsor":"Washington University School of Medicine","biomarkers":" EGFR • ALK • TP53 • FLT1","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • RET rearrangement","tags":["EGFR • ALK • TP53 • FLT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nintedanib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/07/2015","start_date":" 05/07/2015","primary_txt":" Primary completion: 01/09/2020","primary_completion_date":" 01/09/2020","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-11"},{"id":"e5e2b950-7554-4958-b2db-713f66c51761","acronym":"","url":"https://clinicaltrials.gov/study/NCT03280030","created_at":"2021-01-18T16:11:51.281Z","updated_at":"2025-02-25T15:42:59.213Z","phase":"Phase 2","brief_title":"A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML","source_id_and_acronym":"NCT03280030","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FLT3 • PML","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3 • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • midostaurin • daunorubicin"],"overall_status":"Completed","enrollment":" Enrollment 67","initiation":"Initiation: 04/06/2018","start_date":" 04/06/2018","primary_txt":" Primary completion: 11/14/2022","primary_completion_date":" 11/14/2022","study_txt":" Completion: 11/14/2022","study_completion_date":" 11/14/2022","last_update_posted":"2025-02-11"},{"id":"984a9572-0002-4941-9116-d4a0af76671f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05268003","created_at":"2022-03-07T18:53:49.340Z","updated_at":"2025-02-25T15:27:17.213Z","phase":"Phase 2","brief_title":"A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT05268003","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Iclusig (ponatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 06/07/2022","start_date":" 06/07/2022","primary_txt":" Primary completion: 10/05/2026","primary_completion_date":" 10/05/2026","study_txt":" Completion: 10/05/2026","study_completion_date":" 10/05/2026","last_update_posted":"2025-02-10"},{"id":"277136d1-0119-42be-9629-e04f1cfca67d","acronym":"TRIDENT-1","url":"https://clinicaltrials.gov/study/NCT03093116","created_at":"2021-01-17T17:11:31.349Z","updated_at":"2025-02-25T16:31:09.380Z","phase":"Phase 1/2","brief_title":"A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements","source_id_and_acronym":"NCT03093116 - TRIDENT-1","lead_sponsor":"Turning Point Therapeutics, Inc.","biomarkers":" ALK • ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" ROS1 fusion","tags":["ALK • ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Augtyro (repotrectinib) • midazolam hydrochloride"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 03/07/2017","start_date":" 03/07/2017","primary_txt":" Primary completion: 02/29/2028","primary_completion_date":" 02/29/2028","study_txt":" Completion: 02/29/2028","study_completion_date":" 02/29/2028","last_update_posted":"2025-02-07"},{"id":"83a8f7d9-9fcf-4758-bab6-3b6024965562","acronym":"NCI-2018-01186","url":"https://clinicaltrials.gov/study/NCT03147612","created_at":"2022-04-24T08:58:28.491Z","updated_at":"2025-02-25T16:31:11.081Z","phase":"Phase 2","brief_title":"Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03147612 - NCI-2018-01186","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • Iclusig (ponatinib) • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • Truxima (rituximab-abbs) • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 02/08/2018","start_date":" 02/08/2018","primary_txt":" Primary completion: 02/28/2027","primary_completion_date":" 02/28/2027","study_txt":" Completion: 02/28/2027","study_completion_date":" 02/28/2027","last_update_posted":"2025-02-07"},{"id":"b9c34573-0235-40cd-9198-16fe6c36e675","acronym":"HBCH-RT-2021-01","url":"https://clinicaltrials.gov/study/NCT05021328","created_at":"2021-08-25T14:53:25.228Z","updated_at":"2025-02-25T16:32:34.697Z","phase":"Phase 1","brief_title":"Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC","source_id_and_acronym":"NCT05021328 - HBCH-RT-2021-01","lead_sponsor":"Hubei Cancer Hospital","biomarkers":" EGFR • ALK • ROS1","pipe":"","alterations":" ","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Loqtorzi (toripalimab-tpzi)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 02/05/2025","primary_completion_date":" 02/05/2025","study_txt":" Completion: 02/05/2025","study_completion_date":" 02/05/2025","last_update_posted":"2025-02-07"},{"id":"868ab017-feca-462a-908a-0cf81a5b86b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04310007","created_at":"2021-01-18T20:53:46.863Z","updated_at":"2025-02-25T16:37:47.177Z","phase":"Phase 2","brief_title":"Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04310007","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • KRAS • BRAF • ALK • ROS1","pipe":" | ","alterations":" KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative","tags":["EGFR • PD-L1 • KRAS • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • gemcitabine • docetaxel • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cyramza (ramucirumab) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • lexatumumab (ETR2-ST01) • liposomal gemcitabine (FF-10832)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 117","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-06"},{"id":"a58385e3-f746-48dd-bf8f-10d8e83d28bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT01708954","created_at":"2021-01-18T07:26:37.698Z","updated_at":"2025-02-25T16:36:12.668Z","phase":"Phase 2","brief_title":"Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer","source_id_and_acronym":"NCT01708954","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • KRAS • BRAF • RET","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • RET mutation • RET rearrangement • EGFR L858R + EGFR exon 19 deletion","tags":["HER-2 • KRAS • BRAF • RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • RET mutation • RET rearrangement • EGFR L858R + EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 02/13/2013","start_date":" 02/13/2013","primary_txt":" Primary completion: 08/14/2015","primary_completion_date":" 08/14/2015","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2025-02-06"},{"id":"b94d473a-a828-47ba-9b4c-363678434e70","acronym":"PDIGREE","url":"https://clinicaltrials.gov/study/NCT03793166","created_at":"2021-01-18T18:45:15.236Z","updated_at":"2025-02-25T16:44:31.244Z","phase":"Phase 3","brief_title":"Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study","source_id_and_acronym":"NCT03793166 - PDIGREE","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1175","initiation":"Initiation: 06/07/2019","start_date":" 06/07/2019","primary_txt":" Primary completion: 09/15/2025","primary_completion_date":" 09/15/2025","study_txt":" Completion: 09/15/2025","study_completion_date":" 09/15/2025","last_update_posted":"2025-02-06"},{"id":"fe45fba3-5034-46b7-8f07-75aabce5003c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01841736","created_at":"2023-11-14T21:13:55.188Z","updated_at":"2025-02-25T16:36:15.225Z","phase":"Phase 2","brief_title":"Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors","source_id_and_acronym":"NCT01841736","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CHGA","pipe":"","alterations":" ","tags":["CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pazopanib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 171","initiation":"Initiation: 09/20/2013","start_date":" 09/20/2013","primary_txt":" Primary completion: 03/05/2019","primary_completion_date":" 03/05/2019","study_txt":" Completion: 09/13/2025","study_completion_date":" 09/13/2025","last_update_posted":"2025-02-06"},{"id":"6b19c0a6-ae66-4201-9c5b-978c28f8c121","acronym":"","url":"https://clinicaltrials.gov/study/NCT04514484","created_at":"2021-01-18T21:38:07.896Z","updated_at":"2025-02-25T16:45:04.992Z","phase":"Phase 1","brief_title":"Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV","source_id_and_acronym":"NCT04514484","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD276 • VTCN1 • CD4 • HHLA2","pipe":"","alterations":" ","tags":["CD276 • VTCN1 • CD4 • HHLA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/22/2021","start_date":" 11/22/2021","primary_txt":" Primary completion: 11/02/2025","primary_completion_date":" 11/02/2025","study_txt":" Completion: 11/02/2025","study_completion_date":" 11/02/2025","last_update_posted":"2025-02-05"}]